Moderna, Inc. (NASDAQ:MRNA – Free Report) – Equities research analysts at Brookline Capital Markets decreased their FY2029 EPS estimates for Moderna in a research note issued on Monday, August 31st. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings of $11.54 per share for the year, down from their previous forecast of $11.69. Brookline Capital Markets has a “Buy” rating on the stock. The consensus estimate for Moderna’s current full-year earnings is ($6.11) per share. Brookline Capital Markets also issued estimates for Moderna’s FY2030 earnings at $19.11 EPS.
A number of other equities research analysts have also issued reports on MRNA. Loop Capital set a $135.00 price target on Moderna in a research note on Wednesday, August 19th. Barclays boosted their price objective on Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a research report on Monday, August 24th. Piper Sandler reaffirmed an “overweight” rating on shares of Moderna in a research note on Monday, August 3rd. Jefferies Financial Group reiterated a “hold” rating on shares of Moderna in a research report on Wednesday, August 19th. Finally, CLSA upgraded Moderna to an “outperform” rating in a research report on Friday. Seven investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $80.53.
Moderna Stock Up 1.7%
MRNA opened at $140.34 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. Moderna has a fifty-two week low of $22.28 and a fifty-two week high of $176.66. The firm’s fifty day moving average is $78.73 and its 200 day moving average is $60.54. The stock has a market cap of $56.03 billion, a price-to-earnings ratio of -17.56 and a beta of 0.91.
Moderna (NASDAQ:MRNA – Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. The business had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company’s revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the business posted ($2.13) earnings per share.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Moderna in the second quarter worth about $2,142,877,000. California State Teachers Retirement System grew its holdings in Moderna by 6,698.1% during the 2nd quarter. California State Teachers Retirement System now owns 27,681,318 shares of the company’s stock valued at $1,938,523,000 after buying an additional 27,274,128 shares in the last quarter. Capital World Investors purchased a new position in Moderna during the 4th quarter valued at approximately $378,299,000. Theleme Partners LLP bought a new stake in Moderna in the 2nd quarter worth approximately $564,272,000. Finally, Alyeska Investment Group L.P. bought a new stake in Moderna in the 4th quarter worth approximately $95,209,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.
Insider Buying and Selling at Moderna
In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the sale, the insider owned 67,468 shares in the company, valued at $3,373,400. The trade was a 4.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the sale, the president owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.80% of the company’s stock.
Trending Headlines about Moderna
Here are the key news stories impacting Moderna this week:
- Positive Sentiment: Moderna and Merck reported encouraging results from their cancer-vaccine collaboration, supporting Moderna’s strategy to expand beyond COVID-19 vaccines into personalized oncology treatments. The results have attracted positive attention from market commentator Jim Cramer and helped drive investor enthusiasm. Jim Cramer Called Moderna Inc. and Merck’s Trial Results Encouraging
- Positive Sentiment: Recent clinical evidence has provided a major boost to the broader mRNA sector after a difficult period for the technology. Coverage highlights the potential medical and commercial significance of Moderna’s cancer-vaccine work, particularly as the company seeks to establish growth drivers beyond respiratory vaccines. After a Rough Stretch, mRNA Gets a Boost
- Positive Sentiment: Moderna received FDA approval for updated Spikevax and mNEXSPIKE COVID-19 vaccines targeting the latest SARS-CoV-2 subvariant, as well as mFlusiva, its first mRNA influenza vaccine for adults aged 50 and older. The approvals broaden its respiratory portfolio and could improve the company’s long-term commercial opportunity in seasonal vaccines. What Do Moderna FDA Vaccine Approvals Mean for Its Respiratory Push?
- Positive Sentiment: Argus upgraded Moderna to “Buy,” adding a more bullish analyst view following the company’s clinical and regulatory developments. Argus Upgrades Moderna to Buy
- Neutral Sentiment: Trading volume increased significantly after the analyst upgrade, indicating heightened investor interest and strong momentum in MRNA shares. However, heavy activity can also reflect short-term speculation following the stock’s steep rally. Moderna Sees Large Volume Increase After Analyst Upgrade
- Negative Sentiment: Analysts overall maintain an average “Hold” rating, signaling that Wall Street remains cautious despite the recent clinical progress. The stock’s rapid appreciation has also raised concerns about valuation and the risk of profit-taking if additional trial results do not meet high expectations. Moderna Receives Average Rating of Hold
Moderna Company Profile
Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.
Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.
Featured Articles
- Five stocks we like better than Moderna
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
